Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.66 USD
-0.03 (-1.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.65 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 141 - 160 ( 400 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sotagliflozin for Type 1 Diabetes: ADA Presentations Strengthen Clinical Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sotagliflozin for T1D: Three for Three with InTandem3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 5
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of May 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Wedbush Best Ideas List Update.
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Update Key Efficacy Data from Secondary Endpoints from InTandem1 Expected This Month.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q17: Early Xermelo Launch Efforts Look Promising; Additional Sota Readouts Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List: Update
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List: Update
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY16 Update; Path forward for Sotagliflozin in Type 1 Diabetes Could be Defined this Year; Reiterate OUTPERFORM and $38 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L